Loading...

Alexa Fluor® 700 anti-mouse I-A/I-E Antibody

Pricing & Availability
Clone
M5/114.15.2 (See other available formats)
Regulatory Status
RUO
Other Names
MHC class II
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_M5slash114_Alx700_020608
C57BL/6 mouse splenocytes were stained with anti-mouse I-A/I-E (clone M5/114.15.2)Alexa Fluor® 700 (filled histogram) or rat IgG2b, κ Alexa Fluor® 700 isotype control (open histogram).
  • 1_M5slash114_Alx700_020608
    C57BL/6 mouse splenocytes were stained with anti-mouse I-A/I-E (clone M5/114.15.2)Alexa Fluor® 700 (filled histogram) or rat IgG2b, κ Alexa Fluor® 700 isotype control (open histogram).
  • 34_Mouse_Spleen_F480_MHCII
    Confocal image of C57BL/6 mouse spleen sample acquired using the IBEX method of highly multiplexed antibody-based imaging: MHCII (blue) in Cycle 2 and F4/80 (magenta) in Cycle 2. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
  • 39_Mouse_Thymus_CD68_MHCII
    Confocal image of C57BL/6 mouse thymus sample acquired using the IBEX method of highly multiplexed antibody-based imaging: CD68 (cyan) in Cycle 3 and MHCII (red) in Cycle 3. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
  • 45_Mouse_Lung_EpCAM_MHCII_CD169
    Confocal image of C57BL/6 mouse lung sample acquired using the IBEX method of highly multiplexed antibody-based imaging: EpCAM (blue) in Cycle 2, MHCII (magenta) in Cycle 2, and CD169 (green) in Cycle 4. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
  • 51_Mouse_Gut_EpCAM_CD31_MHCII
    Confocal image of C57BL/6 mouse small intestine sample acquired using the IBEX method of highly multiplexed antibody-based imaging: EpCAM (blue) in Cycle 1, CD31 (magenta) in Cycle 2, and MHCII (green) in Cycle 3. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
  • 55_Mouse_Liver_Ecadherin_MHCII
    Confocal image of C57BL/6 mouse liver sample acquired using the IBEX method of highly multiplexed antibody-based imaging: E-Cadherin (blue) in Cycle 1 and MHCII (magenta) in Cycle 4. Tissues were prepared using ~1% (vol/vol) formaldehyde and a detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Images are courtesy of Drs. Andrea J. Radtke and Ronald N. Germain of the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).
Compare all formats See Alexa Fluor® 700 spectral data
Cat # Size Price Quantity Check Availability Save
107621 25 µg £65
Check Availability


Need larger quantities of this item?
Request Bulk Quote
107622 100 µg £148
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

These class II molecules are expressed on antigen presenting cells (including B cells) and a subset of T cells from H-2b,d,q,r bearing mice and are involved in antigen presentation to T cells expressing CD3/TCR and CD4 proteins.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Activated C57BL/6 mouse spleen cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 700 under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

SB - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor® 700 has a maximum emission of 719 nm when it is excited at 633 nm / 635 nm. Prior to using Alexa Fluor® 700 conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.


Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Red Laser (633 nm)
Application Notes

The M5/114.15.2 antibody reacts with a polymorphic determinant shared by the I-Ab, I-Ad, I-Aq, I-Ed, and I-Ek MHC class II alloantigens from mice carrying H-2p,r,q,b,d,u haplotypes. Clone M5/114.15.2 however does not react wtih I-Af, I-Ak, or I-As MHC class II alloantigens.1

Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemistry of frozen sections2,3,6, in vitro and in vivo blocking of antigen presentation or ligand binding4-7, and spatial biology (IBEX)17,18. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 107655 & 107656).

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)
  1. Bhattacharya A, et al. 1981. J. Immunol. 127:2488. (IP)
  2. Viville S, et al. 1993. Cell 72:635. (IHC)
  3. Nelson AJ, et al. 1993. J. Immunol. 151:2453. (IHC)
  4. Shi Y, et al. 1998. J. Exp. Med. 187:367. (Block)
  5. Yamashita I, et al. 1993. Int. Immunol. 5:1139.
  6. Guo M, et al. 1995. Zygote 3:65. (IHC)
  7. Kim A, et al. 2004. Exp. Mol. Med. 36:428. (Block)
  8. Luckashenak NA, et al. 2006. J. Immunol. 177:5177.
  9. Venanzi ES, et al. 2007. J. Immunol. 179:5693.
  10. Christensen SR, et al. 2006. Immunity 25:417. PubMed
  11. Matte-Martone C, et al. 2008. Blood 111:3884. PubMed
  12. De Pascalis R, et al. 2008. Infect. Immun. 76:4311. PubMed
  13. Kuns RD, et al. 2009. Blood 113:5999. PubMed
  14. Sabatino JJ, et al. 2011. J. Exp. Med. 208:81. PubMed
  15. Draber P, et al. 2011. Mol Cell Biol. 22:4550. PubMed
  16. Fu H, et al. 2014. Nat Commun. 5:3436. PubMed
  17. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  18. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Mancini M, et al. 2021. Sci Rep. 11:21171. PubMed
  2. Kuczynski EA, et al. 2022. EMBO Mol Med. 14:e15816. PubMed
  3. Brog RA, et al. 2022. Cancer Immunol Res. 10:962. PubMed
  4. Hindy G, et al. 2022. J Clin Invest. 132: . PubMed
  5. Mansouri S, et al. 2022. J Immunol. 209:2114. PubMed
  6. Tatsumi N, et al. 2022. STAR Protoc. 3:101845. PubMed
  7. Cousin N, et al. 2022. Cells. 12: . PubMed
  8. Sieow JL, et al. 2023. Int J Mol Sci. 24: . PubMed
  9. Zhao K, et al. 2023. Front Immunol. 14:1101769. PubMed
  10. Jameson VJ, et al. 2022. Cytometry A. 101:922. PubMed
  11. Huang W, et al. 2015. J Allergy Clin Immunol. . PubMed
  12. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  13. Mathur R, et al. 2019. Mucosal Immunol. 12:612. PubMed
  14. Hou X, et al. 2020. Cell Reports. 28(1):172-189.e7.. PubMed
  15. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  16. Kwong Chung CK, et al. 2017. Immunology. 150:221. PubMed
  17. Bohrer AC, et al. 2022. Cell Rep. 40:111144. PubMed
  18. Christian DA, et al. 2022. Sci Immunol. 7:eabq7432. PubMed
  19. Bonifacio JPPL, et al. 2022. J Virol. 96:e0087122. PubMed
  20. Lu C, et al. 2023. Antiviral Res. 212:105556. PubMed
  21. Tang Y, et al. 2023. Clin Transl Med. 13:e1237. PubMed
  22. Solier S, et al. 2023. Nature. 617:386. PubMed
  23. Huang T, et al. 2023. Cell Death Dis. 14:354. PubMed
  24. Wiesner DL, et al. 2020. Cell Host Microbe. 614:27. PubMed
  25. Zhang R, et al. 2019. Cell Rep. 28:2647. PubMed
  26. Mancini M, et al. 2019. J Immunol. 202:1479. PubMed
  27. Hewitson JP, et al. 2020. J Immunol. 204:2949. PubMed
  28. Yilmaz B, et al. 2021. Cell Host Microbe. 29(4):650-663.e9. PubMed
  29. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  30. Dong L, et al. 2021. Cancer Cell. . PubMed
  31. Baptista AP et al. 2019. Immunity. 50(5):1188-1201 . PubMed
  32. Pack AD, et al. 2021. Cell Reports. 36:109586. PubMed
  33. Hearnden R, et al. 2021. STAR Protocols. 2(2):100422. PubMed
  34. Earnest JT, et al. 2021. Cell Reports. 35(1):108962. PubMed
  35. Chikina AS, et al. 2020. Cell. 183:411. PubMed
  36. Tordesillas L, et al. 2018. Nat Commun. 9:5238. PubMed
  37. Tyagi AM et al. 2018. Immunity. 49(6):1116-1131 . PubMed
  38. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  39. Hering L, et al. 2021. Int J Mol Sci. 22:. PubMed
  40. Dupont C, et al. 2015. J Immunol. 195: 4369 - 4377. PubMed
  41. Webster HC, et al. 2020. J Immunol Methods. 112702:477. PubMed
  42. Zhang F, et al. 2019. Nat Commun. 10:3974. PubMed
  43. Chan YH, et al. 2019. EMBO Mol Med. 11:e10092. PubMed
  44. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  45. Salei N, et al. 2020. J Am Soc Nephrol. 31:257. PubMed
  46. Uher O, et al. 2021. Cancers (Basel). 13:. PubMed
  47. Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed
  48. Ku MW, et al. 2020. Cell Host Microbe. 29(2):236-249.e6. PubMed
  49. Trompette A, et al. 2022. Mucosal Immunol. :. PubMed
  50. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  51. Korangath P, et al. 2020. Bio Protoc. 10:e3822. PubMed
  52. Ruhland MK, et al. 2020. Cancer Cell. 37(6):786-799.e5. PubMed
  53. Benechet AP, et al. 2019. Nature. 574:200. PubMed
  54. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
  55. Ortiz-Bonilla CJ, et al. 2022. Int J Mol Sci. 23:. PubMed
  56. Sutherland TE, et al. 2021. Frontiers in Immunology. 12:715209. PubMed
  57. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  58. Brandi P, et al. 2022. Cell Rep. 38:110184. PubMed
  59. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  60. Witkowski MT, et al. 2020. Cancer Cell. 37:867. PubMed
  61. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  62. Dieterich LC, et al. 2020. Angiogenesis. 1.24375. PubMed
  63. Dupont C, et al. 2014. PLoS Pathog. 10:1004047. PubMed
  64. Cohen SB et al. 2018. Cell host & microbe. 24(3):439-446 . PubMed
  65. Steuerman Y et al. 2018. Cell systems. 6(6):679-691 . PubMed
  66. Ndeupen S, et al. 2021. iScience. 24:103479. PubMed
  67. Sharma A, et al. 2020. Cell. 183(2):377-394.e21. PubMed
  68. Deerhake ME, et al. 2021. Immunity. 54(3):484-498.e8. PubMed
  69. De Simone G, et al. 2021. Immunity. :. PubMed
  70. Rhys HI, et al. 2018. EBioMedicine. 29:60. PubMed
  71. Macdougall CE et al. 2018. Cell metabolism. 27(3):588-601 . PubMed
  72. Martínez‐López M et al. 2019. Immunity. 50(2):446-461 . PubMed
  73. Casulli J, et al. 2019. Nat Commun. 10:2121. PubMed
  74. Chen YG, et al. 2020. Molecular Cell. 76(1):96-109. PubMed
  75. Liu S, et al. 2020. Cell Host & Microbe. 26(6):779-794.e8.. PubMed
  76. Blriot C, et al. 2021. Immunity. :. PubMed
  77. Liu X, et al. 2020. Cell Host Microbe. 28(5):683-698.e6. PubMed
  78. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  79. Janela B, et al. 2019. Immunity. 50:1069. PubMed
  80. Zhang X, et al. 2021. Mol Cancer Res. 19:1076. PubMed
  81. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  82. Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed
  83. Toshiro Hirai et al. 2019. Immunity. 50(5):1249-1261 . PubMed
  84. Camara A, et al. 2019. Immunity. 50:1467. PubMed
  85. Kim DK, et al. 2022. Nat Commun. 13:6292. PubMed
  86. Zeis P, et al. 2020. Immunity. 53:775. PubMed
  87. Desai P, et al. 2021. Cell. 184(5):1214-1231.e16. PubMed
  88. Mansouri S, et al. 2020. Mucosal Immunol. 0.954861111. PubMed
  89. Teo T, et al. 2015. J Virol. 89: 7955-7969. PubMed
  90. Quiding-Järbrink M, et al. 2010. PLoS One. 5:e15018. PubMed
  91. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  92. Cunha LD et al. 2018. Cell. 175(2):429-441 . PubMed
  93. Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed
  94. Winkler ES, et al. 2020. Cell. 182(4):901-918.e18. PubMed
  95. Draijer C, et al. 2018. Sci Rep. 8:5105. PubMed
  96. Andersen TK, et al. 2019. NPJ Vaccines. 4:9. PubMed
  97. Yousef H, et al. 2019. Nat Med. 25:988. PubMed
  98. Utz SG, et al. 2020. Cell. 181(3):557-573. PubMed
  99. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  100. Montalban-Arques A, et al. 2021. Cell Host Microbe. :. PubMed
  101. Meunier I, et al. 2015. PLoS One. 10: 0138055. PubMed
  102. Salazar V, et al. 2019. Cell Rep. 26:1585. PubMed
  103. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  104. Huang WC, et al. 2020. Adv Mater. 32:e2005637. PubMed
  105. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  106. Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed
  107. Hoyer FF, et al. 2020. Immunity. 51(5):899-914.e7.. PubMed
  108. Ceglia V, et al. 2021. J Immunol. 207:2060. PubMed
  109. Schmit T, et al. 2022. Cell Rep. 38:110456. PubMed
  110. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  111. Ubags ND, et al. 2021. J Allergy Clin Immunol. 1049:147. PubMed
  112. Droho S, et al. 2020. J Vis Exp. . PubMed
  113. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  114. Mogilenko DA et al. 2019. Cell. 177(5):1201-1216 . PubMed
  115. Braza MS et al. 2018. Immunity. 49(5):819-828 . PubMed
  116. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  117. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  118. Rivera CA, et al. 2022. Immunity. 55:129. PubMed
  119. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  120. Lee S, et al. 2021. Autophagy. 18:1062. PubMed
  121. C Khouili S, et al. 2020. Cell Rep. 33:108468. PubMed
  122. Syed I et al. 2018. Cell metabolism. 27(2):419-427 . PubMed
  123. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
RRID
AB_493727 (BioLegend Cat. No. 107621)
AB_493727 (BioLegend Cat. No. 107622)

Antigen Details

Structure
MHC class II
Distribution

B cell and activated T cells, APCs of the H-2b,d,q,r bearing mice

Function
Antigen presentation
Ligand/Receptor
CD3/TCR, CD4
Cell Type
Antigen-presenting cells, B cells, Dendritic cells, T cells, Tregs
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Watts C. 1997. Ann. Rev. Immunol. 15:821.
2. Pamer E, et al. 1998. Ann. Rev. Immunol. 16:323.

Gene ID
14961 View all products for this Gene ID 14969 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
I-A/I-E
Specificity Alt (DOES NOT SHOW ON TDS):
I-A/I-E
App Abbreviation (DOES NOT SHOW ON TDS):
FC,SB
UniProt
View information about I-A/I-E on UniProt.org

Related FAQs

If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?

It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.

Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?

Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.

Are other fluorophores compatible with IBEX?

Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.

The same antibody works in one tissue type but not another. What is happening?

Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.

How can I be sure the staining I’m seeing in my tissue is real?

In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.

Other Formats

View All I-A/I-E Reagents Request Custom Conjugation
Description Clone Applications
Biotin anti-mouse I-A/I-E M5/114.15.2 FC
FITC anti-mouse I-A/I-E M5/114.15.2 FC
PE anti-mouse I-A/I-E M5/114.15.2 FC
Purified anti-mouse I-A/I-E M5/114.15.2 FC,IHC-F,IP,Block
PE/Cyanine5 anti-mouse I-A/I-E M5/114.15.2 FC
APC anti-mouse I-A/I-E M5/114.15.2 FC
Alexa Fluor® 488 anti-mouse I-A/I-E M5/114.15.2 FC,3D IHC
Alexa Fluor® 647 anti-mouse I-A/I-E M5/114.15.2 FC
Pacific Blue™ anti-mouse I-A/I-E M5/114.15.2 FC
Alexa Fluor® 700 anti-mouse I-A/I-E M5/114.15.2 FC,SB
PerCP/Cyanine5.5 anti-mouse I-A/I-E M5/114.15.2 FC
PerCP anti-mouse I-A/I-E M5/114.15.2 FC
APC/Cyanine7 anti-mouse I-A/I-E M5/114.15.2 FC
PE/Cyanine7 anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 421™ anti-mouse I-A/I-E M5/114.15.2 FC,IHC-F,SB
Brilliant Violet 510™ anti-mouse I-A/I-E M5/114.15.2 FC
Purified anti-mouse I-A/I-E (Maxpar® Ready) M5/114.15.2 FC,CyTOF®
Brilliant Violet 605™ anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 650™ anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 711™ anti-mouse I-A/I-E M5/114.15.2 FC
Brilliant Violet 785™ anti-mouse I-A/I-E M5/114.15.2 FC
PE/Dazzle™ 594 anti-mouse I-A/I-E M5/114.15.2 FC
Alexa Fluor® 594 anti-mouse I-A/I-E M5/114.15.2 IHC-F,3D IHC
APC/Fire™ 750 anti-mouse I-A/I-E M5/114.15.2 FC
TotalSeq™-A0117 anti-mouse I-A/I-E M5/114.15.2 PG
Ultra-LEAF™ Purified anti-mouse I-A/I-E M5/114.15.2 FC,IHC-F,IP,Block
TotalSeq™-B0117 anti-mouse I-A/I-E M5/114.15.2 PG
TotalSeq™-C0117 anti-mouse I-A/I-E M5/114.15.2 PG
Spark Blue™ 550 anti-mouse I-A/I-E M5/114.15.2 FC
PE/Fire™ 640 anti-mouse I-A/I-E M5/114.15.2 FC
Spark YG™ 581 anti-mouse I-A/I-E M5/114.15.2 FC
PE/Fire™ 810 anti-mouse I-A/I-E M5/114.15.2 FC
Spark UV™ 387 anti-mouse I-A/I-E M5/114.15.2 FC
Spark Violet™ 538 anti-mouse I-A/I-E M5/114.15.2 FC
PerCP/Fire™ 806 anti-mouse I-A/I-E M5/114.15.2 FC
Spark Red™ 718 anti-mouse I-A/I-E M5/114.15.2 FC
APC/Fire™ 810 anti-mouse I-A/I-E M5/114.15.2 FC
Spark PLUS UV395™ anti-mouse I-A/I-E M5/114.15.2 FC
Go To Top Version: 6    Revision Date: 04/21/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account